ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,996.66
1.00%
US Tech 100
20,877.20
1.72%
다우존스 지수
43,487.83
0.78%
Bitcoin
103,547.47
-0.56%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE

  6. AstraZeneca PLC (AZN) 시세

AstraZeneca PLC

AstraZeneca PLC (AZN)

Astrazeneca Plc
AstraZeneca PLC
AZN Capital Corp
54.17
0.00
(0.00%)
마감 18 1월 6:00AM
15분 지연
0.00
0.00
(0.00%)
시간외 거래: -
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
54.17
매수가
-
매도가
-
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
market_cap
83.972B
전일 종가
54.17
개장가
-
최근 거래 시간
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
-
발행 주식
1,550,163,000
배당수익률
-
주가수익률
28.45
주당순이익(EPS)
3.84
매출
45.81B
순이익
5.96B

AstraZeneca PLC 정보

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from intern... A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
본부
Cambridge, Gbr
설립됨
-

AZN 최신 뉴스

추가 뉴스

EVUSHELD™  significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD group Data published in the New England Journal of...

21 4월 2022
Business Wire

ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

Analysis of Phase III CHAMPION-MG trial open-label extension adds to growing body of safety and efficacy data for ULTOMIRIS in generalized myasthenia gravis Patients who transitioned from...

06 4월 2022
Business Wire

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

Partnership contributes to the AZ Forest global initiative to plant and maintain 50 million trees worldwide by the end of 2025 AstraZeneca has partnered with The National Fish and Wildlife...

24 3월 2022
Business Wire

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs New preclinical authentic ‘live’ virus data from Washington...

21 3월 2022
Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer

First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo’s ENHERTU offer potential to redefine how the disease is classified and treated Positive high-level...

22 2월 2022
Business Wire

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase III trial results show clinically meaningful...

15 2월 2022
Business Wire

Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and...

24 1월 2022
Business Wire

IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years

A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also showed no increase in severe liver toxicity and...

19 1월 2022
Business Wire

IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer

TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting Combination did not increase discontinuations due to adverse events vs...

19 1월 2022
Business Wire

CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

Based on ground-breaking DESTINY-Breast03 results showing AstraZeneca and Daiichi Sankyo’s ENHERTU reduced the risk of disease progression or death by 72% versus trastuzumab emtansine...

18 1월 2022
Business Wire
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

AZN - Frequently Asked Questions (FAQ)

What is the current AstraZeneca share price?
The current share price of AstraZeneca is US$ 54.17
How many AstraZeneca shares are in issue?
AstraZeneca has 1,550,163,000 shares in issue
What is the market cap of AstraZeneca?
The market capitalisation of AstraZeneca is USD 83.97B
What is the 1 year trading range for AstraZeneca share price?
AstraZeneca has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of AstraZeneca?
The price to earnings ratio of AstraZeneca is 28.45
What is the cash to sales ratio of AstraZeneca?
The cash to sales ratio of AstraZeneca is 3.7
What is the reporting currency for AstraZeneca?
AstraZeneca reports financial results in USD
What is the latest annual turnover for AstraZeneca?
The latest annual turnover of AstraZeneca is USD 45.81B
What is the latest annual profit for AstraZeneca?
The latest annual profit of AstraZeneca is USD 5.96B
What is the registered address of AstraZeneca?
The registered address for AstraZeneca is 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA
Which industry sector does AstraZeneca operate in?
AstraZeneca operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ARLAmerican Realty Investors Inc
US$ 15.93
(15.02%)
10.76k
RBOTVicarious Surgical Inc
US$ 16.382
(14.88%)
52.57k
AUNAAuna SA
US$ 8.45
(14.81%)
233.16k
MYTEMYT Netherlands Parent BV
US$ 9.45
(12.23%)
354.61k
BKSYBlackSky Technology Inc
US$ 11.71
(12.06%)
1.7M
SESSES AI Corporation
US$ 0.9369
(-9.91%)
51.58M
DMDesktop Metal Inc
US$ 2.19
(-9.88%)
547.32k
JKSJinkosolar Holdings Co Ltd
US$ 21.23
(-9.81%)
1.55M
BODIBeachbody Company Inc
US$ 6.60
(-9.59%)
19.82k
QBTSD Wave Quantum Inc
US$ 5.275
(-9.21%)
76.53M
QBTSD Wave Quantum Inc
US$ 5.275
(-9.21%)
76.53M
FFord Motor Company
US$ 10.18
(1.70%)
60.8M
BBDBanco Bradesco SA
US$ 1.96
(-1.01%)
59.92M
VALEVale SA
US$ 8.94
(1.94%)
59.4M
SESSES AI Corporation
US$ 0.9369
(-9.91%)
51.58M

토론

전체 피드 보기
Drugdoctor Drugdoctor 5 분 전
Here is our CEO's stock chart pattern... Soon we will see $SRNW sporting the same pattern.

https://investorshub.advfn.com/uimage/uploads/2025/1/17/yrkgpGVSI_1-17.png
SRNW
AlwaysOptimistic AlwaysOptimistic 5 분 전
I also saw that. Of course Chambers would take that position. He has a lot of capital invested in AI with his venture funding and a lot to lose if investors siphon money away from AI in to quantum. Just like NVDIA. This too shall pass IMO.
IONQ
SSKILLZ1 SSKILLZ1 6 분 전
Why Pete would play there now is beyond me. Maybe he has a love of public humiliation?

I have no clue why either. At this point. Which is why I would be shocked if he comes back at this point.

One thing for sure: any Mets solution at first base that includes regularly p
4u2nv2 4u2nv2 6 분 전
I have looked at a lot of charts on IFUS. 1M, 1Y, 5Y and I specifically focused on the volume and PPS movement. I did say recently that I am not trading this stock. I do not own any or plan on buying it. I am more focused on a private business model than trading OTC or any stocks. But the IFUS PPS h
IFUS
nowwhat2 nowwhat2 6 분 전
Charts are just totally freaking SCREAMING that it COULD be a "sell The News" Event......and yet ?

It's like.....



https://investorshub.advfn.com/uimage/uploads/2025/1/17/zvqmlxrp_!_17_hyper_845pm_CALVIN_INAUG_PARADE_ATH.jpg



XRPUSD
littlejohn littlejohn 6 분 전
SMCI will be at 47 to 48 in a Pop

before we can read the 10K

filing header...

That is why you gotta be ready before

it is filed...

Around $48 is the recent trading high

that market makers marked that may
SMCI
Drugdoctor Drugdoctor 8 분 전
Remember, assets from other stock mergers will be added to $FORW's holding company. Right now, something is happening with American Blockchain ($GVSI), our CEO's other shell, and if it is the first to merger, some assets will be coming here. Can't wait for $FORW's chart to look like this.
FORW
MONTANAJOE MONTANAJOE 8 분 전
Just amuse each other with their nonsense!
NBRI
TucsonPhil TucsonPhil 8 분 전
Wow. According to OTC markets, the OS count is now 5,988,649,454. Last time I checked was last year, and I recall it was around 3.9B, when the AS was 5B, then they raised the AS to 10B and have been busy with quite a bit of dilution.
KGKG
MONTANAJOE MONTANAJOE 8 분 전
Like it better when they just talk to each other and leave everyone else alone!!
NBRI
againstallodds againstallodds 10 분 전
https://investorshub.advfn.com/uimage/uploads/2025/1/17/rarvyIMG_0265.jpeg

0.5 oz of rhodium per ton of ore can be considered a very high-grade deposit. Here's why:
* Rhodium is extremely rare: It's one of the rarest and most valuable precious metals.
* Typical grades
NBRI
EarningsCentral EarningsCentral 13 분 전
TLRY
Drugdoctor Drugdoctor 14 분 전
Who made 300% gains-with-George-Sharp's-$GVSI??>>

https://investorshub.advfn.com/uimage/uploads/2025/1/17/yrkgpGVSI_1-17.png
GVSI
axelvento axelvento 14 분 전
Moderna is preparing to advance mRNA-1018 into Phase 3. The Company looks forward to sharing the Phase 1/2 results at an upcoming scientific meeting.
MRNA
gitreal gitreal 15 분 전
Could it be Mt Vernon assays are flawed, and that the extraordibary Rhodiun assays are skewed ?

Skewed? No.
Made up? Yes.
NBRI
Drugdoctor Drugdoctor 16 분 전
Check the accumulation line on chart>>>

https://investorshub.advfn.com/uimage/uploads/2025/1/17/yrkgpGVSI_1-17.png
GVSI
sylvia07 sylvia07 16 분 전
Where are the BASHERS when good news is announced, always missing?
GRST
dinogreeves dinogreeves 16 분 전
Only time will tell which direction they take. In either case, let's get the FID first and hopefully merger not too long after. This is ripe for massive move, with the latest on the media and the Senators in the mix, now imagine that with the merger news and Motley Fool article a long while back w
TGLO
againstallodds againstallodds 17 분 전
Why no mining at Mt Vernon???

Closer to the mill than Fran
NBRI
gitreal gitreal 18 분 전
You're so clever.
AABB
georgie18 georgie18 18 분 전
Your very welcome…🥳
KULR
RobotDroid RobotDroid 19 분 전
Won't hold up next week as the lack of news from mute inept nonmanagement will continue as January falls to February.
NWBO
georgie18 georgie18 19 분 전
Nope…🥳
UMAV
dinogreeves dinogreeves 19 분 전
Also true.
TGLO
dinogreeves dinogreeves 21 분 전
Chen on my previous post I explained the scenario with NUK*K. Number one reason it ran the way it did was the publicity it had with Iron Dome for Israel, second it ran because of the demand it had for a low float, third and most important and must remember, no options, stocks that have no options a
TGLO

최근 히스토리

NYSE
AZN
AstraZeneca
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유